Hong Chao-Qun, Weng Xue-Fen, Huang Xu-Chun, Chu Ling-Yu, Wei Lai-Feng, Lin Yi-Wei, Chen Liu-Yi, Liu Can-Tong, Xu Yi-Wei, Peng Yu-Hui
Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou 515041, Guangdong, China.
J Cancer. 2021 Mar 5;12(9):2747-2755. doi: 10.7150/jca.57019. eCollection 2021.
We previously found a panel of autoantibodies against multiple tumor-associated antigens (BMI-1, HSP70, MMP-7, NY-ESO-1, p53 and PRDX6) that might facilitate early detection of esophagogastric junction adenocarcinoma and esophageal squamous cell carcinoma. Here we aimed at assessing the diagnostic performance of these autoantibodies in breast cancer patients. Enzyme-linked immunosorbent assay was applied to detect sera autoantibodies in 123 breast cancer patients and 123 age-matched normal controls. We adopted logistic regression analysis to identify optimized autoantibody biomarkers for diagnosis and receiver-operating characteristics to analyze diagnostic efficiency. Five of six autoantibodies, BMI-1, HSP70, NY-ESO-1, p53 and PRDX6 demonstrated significantly elevated serum levels in breast cancer compared to normal controls. An optimized panel composed of autoantibodies to BMI-1, HSP70, NY-ESO-1 and p53 showed an area under the curve (AUC) of 0.819 (95% CI 0.766-0.873), 63.4% sensitivity and 90.2% specificity for diagnosing breast cancer. Moreover, this autoantibody panel could differentiate patients with early stage breast cancer from normal controls, with AUC of 0.805 (95% CI 0.743-0.886), 59.6% sensitivity and 90.2% specificity. Our findings indicated that the panel of autoantibodies to BMI-1, HSP70, NY-ESO-1 and p53 as serum biomarkers have the potential to help detect early stage breast cancer.
我们之前发现了一组针对多种肿瘤相关抗原（BMI-1、HSP70、MMP-7、NY-ESO-1、p53和PRDX6）的自身抗体，这些自身抗体可能有助于早期检测食管胃交界腺癌和食管鳞状细胞癌。在此，我们旨在评估这些自身抗体在乳腺癌患者中的诊断性能。应用酶联免疫吸附测定法检测123例乳腺癌患者和123例年龄匹配的正常对照者的血清自身抗体。我们采用逻辑回归分析来确定用于诊断的优化自身抗体生物标志物，并采用受试者工作特征分析诊断效率。与正常对照相比，六种自身抗体中的五种，即BMI-1、HSP70、NY-ESO-1、p53和PRDX6在乳腺癌患者中的血清水平显著升高。由针对BMI-1、HSP70、NY-ESO-1和p53的自身抗体组成的优化检测组在诊断乳腺癌时的曲线下面积（AUC）为0.819（95%CI 0.766-0.873），灵敏度为63.4%，特异性为90.2%。此外，该自身抗体检测组能够区分早期乳腺癌患者和正常对照者，AUC为0.805（95%CI 0.743-0.886），灵敏度为59.6%，特异性为90.2%。我们的研究结果表明，针对BMI-1、HSP70、NY-ESO-1和p53的自身抗体检测组作为血清生物标志物有潜力帮助检测早期乳腺癌。
